论文部分内容阅读
目的探讨CEACAM1在乳腺癌组织中的表达水平及临床特征。方法应用免疫组化和western blot法检测120例乳腺癌患者及40例乳腺良性病变患者组织中CEACAM1的表达水平,并对患者的年龄、肿瘤类型、肿瘤部位、ER/PR及淋巴结转移等临床因素进行相关性分析研究。结果 CEACAM1在乳腺癌组织中表达阳性率为85.0%,而在乳腺良性病变患者组织中表达阳性率为27.5%,乳腺良性组织的阳性表达率明显低于癌组织,两组之间表达阳性率差异有统计学意义(P<0.05)。CEACAM1的表达阳性率与患者年龄、肿瘤部位、肿瘤类型、淋巴结转移、ER/PR、临床分期及浸润深度均无相关关系(P>0.05)。结论 CEACAM1在乳腺癌组织中为高表达,但与患者的临床特征无关;CEACAM1视为促癌基因,对乳腺癌的发生发展有重要作用,并对判断乳腺癌的预后有潜在的价值。
Objective To investigate the expression and clinical features of CEACAM1 in breast cancer. Methods Immunohistochemistry and western blot were used to detect the expression of CEACAM1 in 120 cases of breast cancer and 40 cases of benign breast lesions. The clinical data of CEACAM1 were analyzed including age, tumor type, tumor location, ER / PR and lymph node metastasis Conduct correlation analysis. Results The positive rate of CEACAM1 in breast cancer tissues was 85.0%, while the positive rate in CEA tissues was 27.5%. The positive rate of CEACAM1 in benign breast tissues was significantly lower than that in cancerous tissues. The positive rate of CEACAM1 expression between the two groups was significantly different There was statistical significance (P <0.05). The positive rate of CEACAM1 expression had no correlation with patient age, tumor location, tumor type, lymph node metastasis, ER / PR, clinical stage and depth of invasion (P> 0.05). Conclusion CEACAM1 is overexpressed in breast cancer tissues but not related to the clinical features of the patients. CEACAM1 is considered as a pro-oncogene and plays an important role in the occurrence and development of breast cancer and has potential value in judging the prognosis of breast cancer.